Anastrozole shows promise for early breast cancer

BMJ 2002; 324 doi: (Published 29 June 2002) Cite this as: BMJ 2002;324:1539
  1. Susan Mayor
  1. London

    The aromatase inhibitor anastrozole (Arimidex) has shown similar disease-free survival but fewer side effects than the established treatment, tamoxifen, in a major trial of postmenopausal women with hormone sensitive, early breast cancer (Lancet 2002;359:2131-9).

    First results from the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial showed a small but non-significant increase in disease-free survival at three years with anastrozole (89.4% compared with 87.4% with tamoxifen (hazard ratio 0.83; 95% confidence interval …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription